Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis (NMDARE-HSE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04339127|
Recruitment Status : Recruiting
First Posted : April 9, 2020
Last Update Posted : April 9, 2020
Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate.
One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis.
The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.
|Condition or disease||Intervention/treatment|
|Autoimmune Encephalitis Anti NMDA Receptor Encephalitis Herpetic Encephalitis||Other: Description and analysis|
|Study Type :||Observational|
|Estimated Enrollment :||12 participants|
|Official Title:||Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature|
|Actual Study Start Date :||April 1, 2020|
|Estimated Primary Completion Date :||June 1, 2020|
|Estimated Study Completion Date :||October 1, 2020|
Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
Other: Description and analysis
Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
- Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution. [ Time Frame: at 6 and 12 months ]Retrospective collection of clinical, diagnostic and therapeutic data, evolution at 6 and 12 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04339127
|Contact: Jérôme Honnorat, PhD||04 72 35 78 email@example.com|
|Contact: Géraldine PICARDfirstname.lastname@example.org|
|Hospice Civils de Lyon||Recruiting|
|Bron, France, 69500,|
|Contact: JEROME HONNORAT, PhD 04 72 35 78 06 email@example.com|
|Study Director:||Jérôme Honnorat||National Reference Center of autoimmune encephalitis|